Published date: Oct 04 2024

Journal Title: KnE Life Sciences

Issue title: 4th International Conference in Social Science (4th ICONISS): Healthcare

Pages: 196–204

DOI: 10.18502/kls.v8i2.17372

Rhea Veda Nugrahadr.rheaveda@gmail.comDepartment of Pharmacology, Faculty of Medicine, Universitas Jenderal Achmad Yani, Cimahi

Odih FahruziDepartment of Emergency, Faculty of Medicine, Universitas Jenderal Achmad Yani, Cimahi

Siti Fajah FajriyahFaculty of Medicine, Universitas Jenderal Achmad Yani, Cimahi

Hypertension is known to affect more than one billion people globally and is estimated to increase to 1.5 billion by 2025. It is considered one of the leading causes of death and cardiovascular disease worldwide. The safety of long-term antihypertensive use is also a concern. Through a narrative or literature review, this study evaluated antihypertensive agents based on the results of various literature searches. Researchers reviewed the safety and tolerability of five classes of antihypertensive agents such as Diuretics, Angiotensin-Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB), Beta-Blockers, and Calcium Channel Blockers (CCB). The use of ARB antihypertensive drugs like valsartan is well tolerated and safe. Moreover, the mortality rate associated with enalapril was 16% lower (95% CI 0.76-0.93; P < 0.001). Captopril and lisinopril of Angiotensin-converting Enzyme Inhibitors (ACEIs) have significant side effects (SEs) compared to any antihypertensive drug. Therefore, this study recommends using the ACEIs group, especially captopril and lisinopril, due to the minimal side effects produced compared to other antihypertensive drugs. In addition, the CCBs or Ca antagonists class like amlodipine is potentially well tolerated and safe as a first-line drug for hypertension treatment.

Keywords: antihypertensive drugs, hypertension, safety, side effect, tolerability

[1] Dinarti LK, Anggrahini DW, Lilyasari O, Siswanto BB, Hartopo AB. Pulmonary arterial hypertension in Indonesia: current status and local application of international guidelines. Glob Heart. 2021 Apr;16(1):23.

[2] Zirpe KG, Seta B, Gholap S, Aurangabadi K, Gurav SK, Deshmukh AM, et al. Incidence of medication error in critical care unit of a tertiary care hospital: where do we stand? Indian J Crit Care Med. 2020 Sep;24(9):799–803.

[3] Rossi GP, Rossitto G, Maifredini C, Barchitta A, Bettella A, Cerruti L, et al. Modern management of hypertensive emergencies. High Blood Press Cardiovasc Prev. 2022 Jan;29(1):33–40.

[4] Dzudie A, Barche B, Zomene F, Ebasone PV, Nkoke C, Mouliom S, et al. Real- World Effectiveness and Safety of Two-Drug Single Pill Combinations of Antihypertensive Medications for Blood Pressure Management: A Follow-Up on Daily Cardiology Practice in Douala, Cameroon. Adv Ther. 2023 May;40(5):2282–95.

[5] Lopez EO, Parmar M, Pendela VS, Terrell JM. Lisinopril. In: StatPearls [Internet]. Statpearls publishing; 2023.

[6] Goyal A, Cusick AS, Thielemier B. ACE inhibitors. 2017.

[7] Marte F, Sankar P, Cassagnol M. Captopril. 2018.

[8] Plosker GL, McTavish D. Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease. Drugs Aging. 1995 Sep;7(3):226–53.

[9] Greene SJ, Choi S, Lippmann SJ, Mentz RJ, Greiner MA, Hardy NC, et al. Clinical effectiveness of sacubitril/valsartan among patients hospitalized for heart failure with reduced ejection fraction. J Am Heart Assoc. 2021 Aug;10(16):e021459.

[10] Sauer AJ, Cole R, Jensen BC, Pal J, Sharma N, Yehya A, et al. Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev. 2019 Mar;24(2):167–76. [11]Grossman E, Messerli FH. Long-term safety of antihypertensive therapy. Prog Cardiovasc Dis. 2006;49(1):16–25.

[12] Giovinazzo S, Carmisciano L, Toma M, Benenati S, Tomasoni D, Sormani MP, et al. Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2021 Oct;8(5):3547–56.

[13] Rossello X, Pocock SJ, Julian DG. Long-term use of cardiovascular drugs: challenges for research and for patient care. J Am Coll Cardiol. 2015 Sep;66(11):1273–85.

[14] Brittain HG. Profiles of drug substances, excipients, and related methodology. Academic press; 2020.

[15] Ji Y, Chen S, Wang Q, Xiang B, Xu Z, Zhong L, et al. Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management. Sci Rep. 2018 Mar;8(1):4264.

[16] Khan S, Muhammad T, Rashid YA. Efficacy of furosemide in methotrexate clearance in patients treated with high dose methotrexate. Hematol Transfus Cell Ther. 2022;44:S34.

[17] Khan TM, Patel R, Siddiqui AH. Furosemide. 2018.

[18] Uemura Y, Watanabe T, Ozaki Y, Shimojo M, Imai R, Ishikawa S, et al. Clinical safety and efficacy of long-term use of tolvaptan after discharge in patients with heart failure. J Card Fail. 2017;23(10):S63.

[19] Lee J, Choi J, Yum Y, Joo HJ, Kim YH, An H, et al. Clinical effectiveness and safety of amlodipine/losartan-based single-pill combination therapy in patients with hypertension: findings from real-world, multicenter observational databases. J Clin Hypertens (Greenwich). 2021 Nov;23(11):1975–83.